Eli Lilly is pouring another $4.5 billion into expanding drug manufacturing and development. The diabetes treatment maker ...
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
Eli Lilly (LLY) is reportedly looking to study its weight-loss drug Zepbound in people who aren't considered overweight but ...
PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded ...
As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...
The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback